Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study

Aycardi E.; Bigal M.; McDonald M.; Noble R.; Loupe P.

首页> 外文期刊>Headache >Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study

【24h】

Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study

机译：Fremanezumab（原TEV-48125）降低偏头痛症状，如恶心，呕吐，畏光和阴光恐惧症，并减少在HFEM研究中的第一周治疗中对急性药物的需求

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2017年第3期|共2页
作者
Aycardi E.; Bigal M.; McDonald M.; Noble R.; Loupe P.;
展开▼
作者单位

Teva Pharmaceut Ind Res &

Dev Frazer PA USA;

Teva Pharmaceut Ind Res &

Dev Frazer PA USA;

Teva Pharmaceut Ind Frazer PA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study [J] . Aycardi E., Bigal M., McDonald M., Headache . 2017,第Suppla3期

机译：Fremanezumab（原TEV-48125）降低偏头痛症状，如恶心，呕吐，畏光和阴光恐惧症，并减少在HFEM研究中的第一周治疗中对急性药物的需求
2. Fremanezumab (formerly TEV-48125) Reduces Headache Pain Within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study [J] . Aycardi E., Bigal M., McDonald M., Headache . 2017,第Suppla3期

机译：Fremanezumab（以前Tev-48125）在第2期开始治疗的第一周内降低头痛疼痛
3. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials [J] . Singh Rashmi B. Halker, Aycardi Ernesto, Bigal Marcelo E., Cephalalgia . 2019,第1期

机译：偏头发日持续减少，中度至严重的头痛日和急性用药用于急性药物的患者和CM患者服用FREMANEZUMAB：HOC分析来自第2阶段试验
4. Obsessive-compulsive disorder (OCD): An outcome study. Does treatment in an outpatient setting using cognitive-behavioral group therapy (CBGT) and exposure/response prevention therapy (ERP) reduce symptoms of OCD? [D] . Covington-Kent, Dawna Marie. 2002

机译：强迫症（OCD）：一项结局研究。在门诊环境中使用认知行为小组疗法（CBGT）和暴露/反应预防疗法（ERP）进行治疗是否可以减轻强迫症的症状？
5. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label parallel-group single-dose study in healthy subjects [O] . C Ellero, J Han, S Bhavsar, -1

机译：预防性使用止吐药可减少与艾塞那肽治疗相关的恶心和呕吐：一项针对健康受试者的开放标签平行分组单剂量研究的回顾性分析
6. Chemotherapy is one of the therapies for cancer patients that cause some side effects, one of them is nausea and vomiting. Nausea and vomiting are still felt by patients even though they take antiemetics. Nausea dan vomiting can cause fluid and electrolyte imbalance. The aim of this study was to analysis the effect of combination acupressure wristband and antiemetic among chemotherapy induced nausea vomiting (CINV) on breast cancer patients. This research used quasi experimental research method, with a pre-post test with the control group. The sampling techniques was consecutive sampling with 25 respondents both in intervention group and control group. In the intervention group had received an acupressure wristband. CINV measured on the second day until fourth day after chemotherapy. Nausea and vomiting score were measured twice a day by a telemonitoring methode by Rhodes Index Nausea, Vomiting and Retching (INVR) questionaire. Data were analyzed by paired t-test, independent t-test, Wilcoxon test and Mann Whitney. The result of this study showed that acupressure wristband significantly reduce the chemotherapy induced nausea and vomit (p value = 0.000). The use of acupressure wristband combined with antiemetic therapy can significantly decrease chemotherapy induced nausea and vomiting in breast cancer patients. Acupressure wristband recommended for consideration nursing intervention in treating breast cancer patients who experience nausea and vomiting. [O] . Endah Fatma 2018

机译：化疗是癌症患者的疗法之一，导致一些副作用，其中一个是恶心和呕吐。患者仍然感受到恶心和呕吐，即使他们服用助性学。恶心丹呕吐会导致液体和电解质不平衡。本研究的目的是分析组合组合腕带和抑制在乳腺癌患者中的诱导恶心呕吐（CINV）的影响。本研究使用了准实验研究方法，用对照组进行了预先测试。采样技术是在干预组和对照组中进行25名受访者的连续抽样。在干预组中，收到了一名腕带。 Cinv在化疗后第四天测量。通过罗得岛指数恶心，呕吐和转换（INVR）问卷，每天测量恶心和呕吐分数。通过配对的T检验，独立的T检验，Wilcoxon测试和Mann Whitney分析数据。该研究的结果表明，Acuruce腕带显着降低化疗诱导的恶心和呕吐物（P值= 0.000）。使用Acu压抑腕带与止吐疗法相结合，可以显着降低乳腺癌患者诱导的恶心和呕吐。 Acu压痕腕带推荐用于治疗体验恶心和呕吐的乳腺癌患者的护理干预。

Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study

著录项

相似文献

相关主题

期刊订阅